United Therapeutics (Nasdaq: UTHR) is selling a voucher designed to speed up approval for rare pediatric disease treatments to Chicago-based pharmaceutical company AbbVie Inc. for a record $350 million.
The Wall Street Journal reports the Silver Spring-based biotechnology company landed the voucher when it received approval from the Food and Drug Administration for Unituxin, its drug designed to treat neuroblastoma.